Regenxbio (RGNX) said Tuesday that it has closed its partnership with Japanese pharmaceutical and health food company Nippon Shinyaku.
The clinical-stage company said the agreement requires it and Nippon Shinyaku to develop and commercialize RGX-121 to treat patients with Hunter syndrome, and RGX-111 to treat Hurler syndrome in the US and Asia.
Regenxbio said RGX-121 is set to be the first gene therapy for Hunter syndrome, with FDA approval expected as early as late this year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。